In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sequoia Sciences Inc.

www.sequoiasciences.com

Latest From Sequoia Sciences Inc.

Antibiotics: Start-Ups Ply Novel Targets and Technologies

Microbial drug resistance is a real and growing problem, but drugmakers face disincentives: a plethora of products already on the market, the difficulty of differentiating drugs, and the habit of reserving truly new drugs for emergencies. Big Pharmas are backing out, creating opportunities for small companies who feel they can play successfully. But lack of interest from large partners means biotechs can't access the assets those firms hold, so many start-ups are pairing up with peers. Some firms are building businesses around an abundance of targets derived through genomics. But others are deliberately avoiding working with novel genetic code and instead studying whole cells and physiological changes in organisms. Many firms are addressing the lack of chemical diversity against targets. Some of these are pursuing diversity through natural products like marine microbes, insisting they'll fare better than earlier firms did, in part because of technological advances. Others are trying to create diversity synthetically, by taking structural approaches to understanding targets new and old, as well as compounds. Crystallography, in silico libraries, computational models and mass spectroscopy are key tools in iterative development processes that remain unproven in the anti-infectives field. Some firms are seeking to minimize the risks of novelty, by putting their efforts into developing new versions of antibiotics that worked well before resistance grew. No matter what technological approach start-ups take to developing antibiotics, all face similar challenges external to themselves-primarily in regulatory affairs and funding, but also in hunting Big Pharma partnerships.
BioPharmaceutical Strategy

Analyticon Discovery GmbH

Analyticon Discovery claims to be the world leader in structure elucidation of natural products from plants and microorganisms for drug discovery. The start-up, based in Potsdam, Germany, has four pharmaceutical clients and plans to turn a profit in 2003.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sequoia Sciences Inc.
  • Senior Management
  • Gary Eldridge, Pres. & CEO
    Steven L Trampe, CFO
    Mark O'Neil-Johnson , Dir., Scientific Dev.
  • Contact Info
  • Sequoia Sciences Inc.
    Phone: (858) 623-0800
    11199 Sorrento Valley Road, Suite H
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register